Business Context and Reporting Period
Legend Biotech Corporation filed a Form 6-K on January 21, 2026, reporting preliminary sales data for its product CARVYKTI® for the quarter ended December 31, 2025. The company operates under a Collaboration and License Agreement with Janssen Biotech, Inc. and Janssen Pharmaceutica NV.
Key Financial Metrics
- Net Trade Sales (CARVYKTI®): Approximately $555 million for the quarter ended December 31, 2025.
- Data Source: Figures are based on information provided by Janssen and have not been independently verified by Legend Biotech.
- Revenue Recognition: The determination of final revenue and gross profit to be recorded in consolidated statements is subject to the completion of financial statements for the period.
- Audit Status: Independent registered public accountants have not audited, reviewed, or performed procedures on this data.
- Other Metrics: The filing does not provide clear values for total company revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing does not provide comparative data for the prior period; therefore, material changes versus the prior comparable period cannot be determined from this text.
Guidance, Outlook, and Risks
The report contains forward-looking statements regarding expectations for net trade sales and gross profit of CARVYKTI®. Management disclaims any obligation to update these statements. Key risks and contingencies identified include:
- Uncertainties in new pharmaceutical product development and unexpected clinical trial results.
- Regulatory actions, delays, or requests for additional safety and efficacy data.
- Delays caused by third-party partners.
- Challenges to patent or intellectual property protection, including U.S. litigation.
- Competition and pricing pressures from government and industry.
Investor Verification Checklist
- Verify the final audited revenue and gross profit figures in the upcoming Form 20-F for the period ended December 31, 2025.
- Confirm the accuracy of the $555 million net trade sales figure once independently verified by Legend Biotech.
- Review the "Risk Factors" section of the Annual Report on Form 20-F (filed March 11, 2025) for detailed litigation and regulatory risks.
- Monitor updates on the Collaboration and License Agreement with Janssen for any changes in royalty or profit-sharing terms.